tiprankstipranks
Trending News
More News >
Allurion Technologies, Inc. (ALUR)
:ALUR
US Market

Allurion Technologies (ALUR) Earnings Dates, Call Summary & Reports

Compare
262 Followers

Earnings Data

Report Date
Aug 19, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
-0.81
Last Year’s EPS
-1.25
Same Quarter Last Year
Based on 4 Analysts Ratings

Earnings Call Summary

Earnings Call Date:May 14, 2025
|
% Change Since: 12.71%
|
Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a company in transition with significant strides toward efficiency and profitability, highlighted by improved gross margins, a successful new sales model, and strategic FDA engagement. However, these positive developments are tempered by a decline in revenue due to the temporary suspension of sales in France and ongoing operating losses.
Company Guidance
During Allurion Technologies' first quarter earnings call for fiscal year 2025, the company provided a comprehensive update on its financial performance and strategic initiatives. Revenue for the quarter was reported at $5.6 million, with adjusted operating expenses of $10.1 million, reflecting a 45% decrease compared to the previous year. The adjusted net operating loss was $5.9 million, narrowing by 48% year-over-year, while the gross margin expanded to 75%, up from 73% the previous year and 45% in the prior quarter. The company outlined its five-pillar plan for 2025, which includes a new commercial strategy focusing on key geographies, gaining FDA approval for the Allurion Balloon, achieving profitability for the ex-U.S. business, scaling its AI product platform, and resuming commercialization in France. Allurion also highlighted its efforts to integrate GLP-1 therapies with its products, citing studies demonstrating significant weight loss and improved health metrics. The company maintains its revenue guidance of approximately $3 million, with a 50% reduction in operating expenses compared to 2024, and ended the quarter with $20 million in cash and cash equivalents.
Reduction in Operating Expenses
Adjusted operating expenses were reduced by 45% compared to the prior year, reflecting increased efficiency and progress toward profitability.
Expansion of Gross Margin
Gross margin expanded to 75% compared to 73% in the prior year and 45% in the previous quarter, driven by increased manufacturing efficiencies.
Successful B2B2C Model Implementation
The B2B2C sales model demonstrated over 40% growth quarter-over-quarter and year-over-year in clinics in Europe.
FDA Engagement and Approval Path
Completed pre-PMA meeting with FDA and expect to complete PMA submission by the end of June, with positive feedback on additional analyses.
Progress in France
Reengagement and re-training of clinics in France, with plans to resume commercialization in the second half of the year.
Strong Cash Position
Ended the first quarter with cash and cash equivalents of $20 million, providing a runway for achieving FDA approval and profitability.

Allurion Technologies (ALUR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ALUR Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 19, 2025
2025 (Q2)
-0.81 / -
-1.25
May 14, 2025
2025 (Q1)
-1.57 / 1.46
2.75-47.02% (-1.29)
Mar 26, 2025
2024 (Q4)
-5.70 / -7.95
-1020.50% (+2.05)
Nov 13, 2024
2024 (Q3)
-4.56 / -3.50
-13.40873.90% (+9.91)
Aug 13, 2024
2024 (Q2)
-6.00 / -1.25
-73.96898.31% (+72.72)
May 14, 2024
2024 (Q1)
-7.00 / 2.75
-10.8125.46% (+13.55)
Mar 21, 2024
2023 (Q4)
-12.70 / -10.00
0.32-3225.00% (-10.32)
Nov 13, 2023
2023 (Q3)
- / -13.41
1.962-783.38% (-15.37)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ALUR Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 14, 2025
$2.36$2.92+23.73%
Mar 26, 2025
$3.11$3.12+0.32%
Nov 13, 2024
$17.76$13.08-26.35%
Aug 13, 2024
$19.88$19.46-2.11%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Allurion Technologies, Inc. (ALUR) report earnings?
Allurion Technologies, Inc. (ALUR) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
    What is Allurion Technologies, Inc. (ALUR) earnings time?
    Allurion Technologies, Inc. (ALUR) earnings time is at Aug 19, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ALUR EPS forecast?
          ALUR EPS forecast for the fiscal quarter 2025 (Q2) is -0.81.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis